FDA Adverse Event Injury Summary report: N

INTUITRAK

MDR report key: 5355508 · Received January 8, 2016

Report

Report Number
2031527-2016-00011
Event Type
Injury
Date Received
January 8, 2016
Date of Event
December 9, 2015
Report Date
December 9, 2015
Manufacturer
ENDOLOGIX, INC.
Product Code
MIH
PMA / PMN Number
P040002
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
PA, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE INVOLVED IN THE EVENT WILL NOT BE RETURNED FOR EVALUATION AS IT REMAINS IMPLANTED IN THE PATIENT. IF ADDITIONAL INFORMATION PERTINENT TO THE INCIDENT IS OBTAINED, A FOLLOW-UP REPORT WILL BE SUBMITTED. ADDITIONAL DEVICE: MODEL 20-25-65S LIMB AORTIC EXTENSION LOT: W09-0819-011 REL. DATE: 7/13/2009 EXP. DATE: 2/28/2010. DEVICES REMAIN IMPLANTED IN THE PATIENT.

Additional Manufacturer Narrative · 1

CLINICAL EVALUATION CONFIRMED TYPE 2 ENDOLEAK. PRE-IMPLANT PATIENT DATA WAS NOT AVAILABLE FOR REVIEW. THE EVENT IS NOT A DESIGN OR MANUFACTURING RELATED ISSUE. DEVICE WAS NOT RETURNED, NO EVALUATION COMPLETED. BASED ON THE INVESTIGATION IT IS INCONCLUSIVE, THERE IS NOT ENOUGH INFORMATION TO DETERMINE THE ROOT CAUSE OF THE REPORTED EVENT. CONTRIBUTING FACTORS INCLUDE ANTIPLATELET THERAPY AND ECTASIA OF THE INTERNAL AND EXTERNAL ILIAC PRIOR TO THE INITIAL IMPLANT. PRODUCT LABELING SPECIFIES THE POTENTIAL FOR INCREASED RISK FOR ENDOLEAKS WITH THE PLACEMENT OF A STENT GRAFT.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE PATIENT HAD A PROCEDURE ON (B)(6) 2011 WITH A BIFURCATED, A SUPRARENAL AORTIC EXTENSION, AND TWO LIMB EXTENSIONS. UPON FOLLOW UP, PATIENT WITH AN ECTATIC ILIAC ANEURYSM SHOWED THAT IT HAD GROWN. PHYSICIAN IMPLANTED 4 LIMB EXTENSIONS AND PATIENT IS NOW STABLE.

Description of Event or Problem · 1

CLINICAL EVALUATION CONFIRMED AN ENDOLEAK TYPE 2.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
13118 INTUITRAK LIMB AORTIC EXTENSION MIH ENDOLOGIX, INC. 20-25-55S W11-0498-007

Patients

Seq Age Sex Outcome Treatment
1 80 YR Required Intervention